ClinicalTrials.gg
CompletedNCT02728895Updated Aug 26, 2019Results posted

Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogeneic HSCT

A Phase 1 interventional study of Vedolizumab in Allogeneic Hematopoietic Stem Cell Transplantation, sponsored by Takeda. Completed at 5 sites in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2019-08-26.

Sponsored by Takeda · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The purpose of this study is to assess the initial tolerability, safety and recommended phase 2 dose of vedolizumab intravenous (IV) administered for GvHD prophylaxis along with standard GvHD prophylaxis therapy (in participants undergoing allogeneic hematopoietic stem cell transplantation [allo-HSCT]).

Read the detailed description

The drug being tested in this study is called Vedolizumab. Vedolizumab (also called MLN0002) is approved for the treatment of adult participants with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD) who achieved an inadequate response, had a loss of response, or were intolerant to conventional and/or biologic treatments. This study will look at the tolerability and pharmacokinetics of Vedolizumab in participants undergoing allo-HSCT when added to standard GvHD prophylaxis (tacrolimus plus short-term methotrexate) for the prevention of acute GvHD (major complication in allo-HSCT).

The study will enroll approximately 36 participants. Participants will be assigned to different dose-escalating cohorts in order to find out the recommended phase 2 dose (RP2D) of the study:

  • Cohort 1: Vedolizumab 75 mg
  • Cohort 2: Vedolizumab 300 mg
  • Cohort 3: Vedolizumab Dose 1

All participants have to receive 1 injection of Vedolizumab on Day -1 before allo-HSCT and on Days 13 and 42 after allo-HSCT. If none of the participants receiving vedolizumab at 75 mg experience dose-limiting toxicities (DLTs), dose escalation will continue to 300 mg on Day -1 before allo-HSCT and on Days +13 and +42 after allo-HSCT. If the first 3 participants at 300 mg tolerate the treatment without experiencing DLTs, then the decision on whether to increase the vedolizumab IV dose in the next cohort will be guided by the PK results.

Cohorts will be escalated in same manner until the identification of RP2D. The cohort at that dose level may be expanded to include approximately 18 additional participants undergoing myeloablative conditioning or reduced-intensity conditioning (RIC) and receiving either related or unrelated allo-HSCT for the treatment of hematologic malignancies or myeloproliferative neoplasms. This group of participants will allow the further assessment of the tolerability and clinical activity of vedolizumab.

This multi-center trial will be conducted in the United States. The overall time to participate in this study will be approximately 2 years. Following the treatment period, participants who remain in remission will be followed for development of acute and chronic GvHD and safety during clinic visits at 4, 5, 6, 9, and 12 months after allo-HSCT or until death or withdrawal of consent or termination of the study by the sponsor. Participants who complete the study will attend a 12-month follow-up visit. Patients who have been discontinued from treatment will attend an end of treatment visit 30 to 40 days after the last dose of study drug using all study procedures outlined for the 12-month follow-up visit.

02

Conditions studied

  • Allogeneic Hematopoietic Stem Cell Transplantation

Keywords

  • Drug Therapy
03

In context

Lead sponsor

Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.

Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Is undergoing matched or single-antigen mismatched unrelated-donor myeloablative transplant for the treatment of acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML); Is less than or equal to (\<=) 60 years of age.

    For the cohort after RP2D

  2. Is undergoing matched or single-antigen mismatched related or unrelated-donor transplant and receiving myeloablative conditioning or RIC for the treatment of hematologic or myeloproliferative neoplasms; Is less than or equal to (\<=) 75 years of age.

Exclusion criteria

Exclusion Criteria:

  1. Has received prior transplants or who are planned to undergo umbilical cord blood transplant, receive ex vivo T-cell-depleted hematopoietic stem cells (HSCs), received any in vivo T-cell depleting antibodies, or non-myeloablative conditioning.
  2. Has active cerebral/meningeal disease, active cytomegalovirus (CMV) colitis, or signs and symptoms of progressive multifocal leukoencephalopathy (PML) or any history of PML.
  3. Is undergoing transplant for the treatment of nonmalignant hematological disorders (for example: aplastic anemia, sickle cell anemia, thalassemias, Fanconi anemia).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Cohort 1: Vedolizumab 75 mg

    Vedolizumab 75 mg, injection, intravenously once on Days -1, 13 and 42.

    Drug: Vedolizumab

  • Experimental
    Cohort 2: Vedolizumab 300 mg

    Vedolizumab 300 mg, injection, intravenously once on Days -1, 13 and 42.

    Drug: Vedolizumab

  • Experimental
    Cohort 3: Vedolizumab Dose 1

    Vedolizumab first decided dose as determined from Cohort 1 or 2, injection, intravenously once on Days -1, 13 and 42.

    Drug: Vedolizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-Limiting Toxicities (DLTs)

    DLTs was based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03 and was defined as any of following events: Grade 3 or higher toxicity assessed by the investigator as related to vedolizumab treatment; Grade 4 or higher regimen-related organ toxicities; and failure to engraft by Day +28. Engraftment was defined as absolute neutrophils count (ANC) greater than (\>) 500 per cubic millimeter (/mm\^3) for 3 consecutive days or \>2000/mm\^3 for 1 day.

    Time frame: Baseline up to Day 28

  2. Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Up to 18 weeks after last dose of study drug

  3. Mean Serum Concentrations of Vedolizumab That Helped the Likelihood of Alpha4Beta7 Target Saturation on Day 100 Following Allo-HSCT

    Time frame: Day 100

Secondary outcomes

  1. Time to Neutrophil Engraftment

    Time to neutrophil engraftment (recovery of ANC) was defined by an ANC \>500/mm\^3 for 3 consecutive days or \>2000/mm\^3 for 1 day. Time to neutrophil engraftment was calculated using Kaplan-Meier estimate and presented with 2-sided 95% confidence interval.

    Time frame: Baseline up to Day 100

  2. Percentage of Participants With Overall Grade 2 to 4 Acute Graft-Versus-Host Disease (GvHD)

    GvHD grading scale was based on the modified Glucksberg criteria. The grades are defined as: Grade 1 (skin stage 1 or 2 only); Grade 2 (skin stage 3 or liver stage 1 or lower or gastrointestinal \[GI\] stage 1 or upper GI involvement); Grade 3 (skin stage 0 to 3 plus liver stage 2 to 4 or lower GI stage 2 to 3); Grade 4 (skin stage 4 or lower GI stage 4).

    Time frame: Baseline up to Day 100

  3. Percentage of Participants With Maximum Severity of Acute GvHD Based on Modified Glucksberg Criteria

    Maximum severity was assessed using GvHD grading scale based on the modified Glucksberg criteria. The grades are defined as: Grade 1 (skin stage 1 or 2 only); Grade 2 (skin stage 3 or liver stage 1 or lower or GI stage 1 or upper GI involvement); Grade 3 (skin stage 0 to 3 plus liver stage 2 to 4 or lower GI stage 2 to 3); Grade 4 (skin stage 4 or lower GI stage 4).

    Time frame: Baseline up to Day 100

  4. Percentage of Participants With Maximum Severity of Acute GvHD Based on Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Modified International Bone Marrow Transplant Registry Database (IBMTR) Index

    Maximum severity of acute GvHD was assessed by using BMT CTN modified IBMTR index. The severity index are defined as: Grade A (skin stage 1: extent of rash less than \[\<\] 25%); Grade B (skin stage 2: extent of rash 25 to 50% or liver stage 1 to 2: total bilirubin 34 to 102 micromole per liter \[mcmol/L\] or intestinal tract stage 1 to 2: volume of diarrhea 550 to 1500 milliliter per day \[mL/day\]); Grade C (skin stage 3: extent of rash greater than (\>) 50% or liver stage 3: total bilirubin 103 to 255 mcmol/L or intestinal tract stage 3: volume of diarrhea \>1500 mL/day); Grade D (skin stage 4: extent of rash bullae or liver stage 4: total bilirubin \>255 or intestinal tract stage 4: volume of diarrhea severe pain and ileus).

    Time frame: Baseline up to Day 100

  5. Ctrough: Serum Concentration Before Dosing for Vedolizumab

    Time frame: Days 13 and 42 pre-dose

07

Results

Posted Aug 26, 2019

Participant flow

Participants took part in the study at 5 investigative sites in the United States from 15 June 2016 to 10 July 2018.

Participant flow — Overall Study
MilestoneCohort 1: Vedolizumab 75 mgCohort 2: Vedolizumab 300 mg
Started321
Completed216
Not completed15
Withdrew: Other12
Withdrew: Withdrawal by subject03

Outcome measures

PrimaryNumber of Participants With Dose-Limiting Toxicities (DLTs)

DLTs was based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03 and was defined as any of following events: Grade 3 or higher toxicity assessed by the investigator as related to vedolizumab treatment; Grade 4 or higher regimen-related organ toxicities; and failure to engraft by Day +28. Engraftment was defined as absolute neutrophils count (ANC) greater than (\>) 500 per cubic millimeter (/mm\^3) for 3 consecutive days or \>2000/mm\^3 for 1 day.

Time frame:
Baseline up to Day 28
Reported as:
Count of participants · Participants
Number of Participants With Dose-Limiting Toxicities (DLTs)
ParticipantsCohort 1: Vedolizumab 75 mgCohort 2: Vedolizumab 300 mg
Number of Participants With Dose-Limiting Toxicities (DLTs)00
PrimaryNumber of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame:
Up to 18 weeks after last dose of study drug
Reported as:
Count of participants · Participants
Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
ParticipantsCohort 1: Vedolizumab 75 mgCohort 2: Vedolizumab 300 mg
TEAEs321
SAEs211
PrimaryMean Serum Concentrations of Vedolizumab That Helped the Likelihood of Alpha4Beta7 Target Saturation on Day 100 Following Allo-HSCT
Time frame:
Day 100
Reported as:
Mean · microgram per milliliter (mcg/mL)
Mean Serum Concentrations of Vedolizumab That Helped the Likelihood of Alpha4Beta7 Target Saturation on Day 100 Following Allo-HSCT
microgram per milliliter (mcg/mL)Cohort 1: Vedolizumab 75 mgCohort 2: Vedolizumab 300 mg
Mean Serum Concentrations of Vedolizumab That Helped the Likelihood of Alpha4Beta7 Target Saturation on Day 100 Following Allo-HSCT7.34 ± 3.76218.36 ± 11.043
SecondaryTime to Neutrophil Engraftment

Time to neutrophil engraftment (recovery of ANC) was defined by an ANC \>500/mm\^3 for 3 consecutive days or \>2000/mm\^3 for 1 day. Time to neutrophil engraftment was calculated using Kaplan-Meier estimate and presented with 2-sided 95% confidence interval.

Time frame:
Baseline up to Day 100
Reported as:
Median · days
Time to Neutrophil Engraftment
daysCohort 1: Vedolizumab 75 mgCohort 2: Vedolizumab 300 mg
Time to Neutrophil Engraftment22 (15 to 22)14 (13 to 17)
SecondaryPercentage of Participants With Overall Grade 2 to 4 Acute Graft-Versus-Host Disease (GvHD)

GvHD grading scale was based on the modified Glucksberg criteria. The grades are defined as: Grade 1 (skin stage 1 or 2 only); Grade 2 (skin stage 3 or liver stage 1 or lower or gastrointestinal \[GI\] stage 1 or upper GI involvement); Grade 3 (skin stage 0 to 3 plus liver stage 2 to 4 or lower GI stage 2 to 3); Grade 4 (skin stage 4 or lower GI stage 4).

Time frame:
Baseline up to Day 100
Reported as:
Number · percentage of participants
Percentage of Participants With Overall Grade 2 to 4 Acute Graft-Versus-Host Disease (GvHD)
percentage of participantsCohort 1: Vedolizumab 75 mgCohort 2: Vedolizumab 300 mg
Percentage of Participants With Overall Grade 2 to 4 Acute Graft-Versus-Host Disease (GvHD)0 (0 to 70.8)19.0 (5.4 to 41.9)
SecondaryPercentage of Participants With Maximum Severity of Acute GvHD Based on Modified Glucksberg Criteria

Maximum severity was assessed using GvHD grading scale based on the modified Glucksberg criteria. The grades are defined as: Grade 1 (skin stage 1 or 2 only); Grade 2 (skin stage 3 or liver stage 1 or lower or GI stage 1 or upper GI involvement); Grade 3 (skin stage 0 to 3 plus liver stage 2 to 4 or lower GI stage 2 to 3); Grade 4 (skin stage 4 or lower GI stage 4).

Time frame:
Baseline up to Day 100
Reported as:
Number · percentage of participants
Percentage of Participants With Maximum Severity of Acute GvHD Based on Modified Glucksberg Criteria
percentage of participantsCohort 1: Vedolizumab 75 mgCohort 2: Vedolizumab 300 mg
Grade 166.7 (17.5 to 95.0)28.6 (11.3 to 55.6)
Grade 20 (NA to NA)14.3 (3.8 to 41.1)
Grade 30 (NA to NA)4.8 (0.6 to 29.7)
Grade 40 (NA to NA)0 (NA to NA)
SecondaryPercentage of Participants With Maximum Severity of Acute GvHD Based on Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Modified International Bone Marrow Transplant Registry Database (IBMTR) Index

Maximum severity of acute GvHD was assessed by using BMT CTN modified IBMTR index. The severity index are defined as: Grade A (skin stage 1: extent of rash less than \[\<\] 25%); Grade B (skin stage 2: extent of rash 25 to 50% or liver stage 1 to 2: total bilirubin 34 to 102 micromole per liter \[mcmol/L\] or intestinal tract stage 1 to 2: volume of diarrhea 550 to 1500 milliliter per day \[mL/day\]); Grade C (skin stage 3: extent of rash greater than (\>) 50% or liver stage 3: total bilirubin 103 to 255 mcmol/L or intestinal tract stage 3: volume of diarrhea \>1500 mL/day); Grade D (skin stage 4: extent of rash bullae or liver stage 4: total bilirubin \>255 or intestinal tract stage 4: volume of diarrhea severe pain and ileus).

Time frame:
Baseline up to Day 100
Reported as:
Number · percentage of participants
Percentage of Participants With Maximum Severity of Acute GvHD Based on Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Modified International Bone Marrow Transplant Registry Database (IBMTR) Index
percentage of participantsCohort 1: Vedolizumab 75 mgCohort 2: Vedolizumab 300 mg
Grade A0 (NA to NA)19.0 (6.1 to 46.2)
Grade B66.7 (17.5 to 95.0)14.3 (3.8 to 41.1)
Grade C0 (NA to NA)14.3 (3.8 to 41.1)
Grade D0 (NA to NA)0 (NA to NA)
SecondaryCtrough: Serum Concentration Before Dosing for Vedolizumab
Time frame:
Days 13 and 42 pre-dose
Reported as:
Mean · mcg/mL
Ctrough: Serum Concentration Before Dosing for Vedolizumab
mcg/mLCohort 1: Vedolizumab 75 mgCohort 2: Vedolizumab 300 mg
Day 135.87 ± 3.0021.34 ± 6.05
Day 428.17 ± 5.2029.05 ± 13.04

Adverse events

Collected over TEAEs are adverse events that started after the first dose of study drug and no more than Week 18 after the last dose of study drug. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: Vedolizumab 75 mg1/3 (33.3%)2/3 (66.7%)3/3 (100%)
Cohort 2: Vedolizumab 300 mg2/21 (9.5%)11/21 (52.4%)21/21 (100%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventCohort 1: Vedolizumab 75 mgCohort 2: Vedolizumab 300 mg
InfluenzaInfections and infestations1/30/21
DiarrhoeaGastrointestinal disorders1/32/21
NauseaGastrointestinal disorders1/32/21
Acute myeloid leukaemia recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/30/21
Failure to thriveMetabolism and nutrition disorders0/32/21
Febrile neutropeniaBlood and lymphatic system disorders0/32/21
HypotensionVascular disorders0/32/21
Acute kidney injuryRenal and urinary disorders0/32/21
PyrexiaGeneral disorders0/32/21
BronchitisInfections and infestations0/31/21
Most frequent other events
Showing 10 of 191
Most frequent other events
EventCohort 1: Vedolizumab 75 mgCohort 2: Vedolizumab 300 mg
StomatitisGastrointestinal disorders3/310/21
FatigueGeneral disorders3/312/21
Alanine aminotransferase increasedInvestigations3/34/21
HypomagnesaemiaMetabolism and nutrition disorders3/317/21
AnaemiaBlood and lymphatic system disorders2/315/21
Platelet count decreasedInvestigations2/315/21
DiarrhoeaGastrointestinal disorders2/313/21
VomitingGastrointestinal disorders2/36/21
PyrexiaGeneral disorders2/311/21
White blood cell count decreasedInvestigations2/37/21

Baseline characteristics

The population of participants evaluable for vedolizumab safety was defined as all participants who received any amount of vedolizumab intravenously.

Age, Continuous
Age, Continuous(years)Cohort 1: Vedolizumab 75 mgCohort 2: Vedolizumab 300 mgTotal
Mean30.0 ± 17.4452.7 ± 16.9049.9 ± 18.27
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1: Vedolizumab 75 mgCohort 2: Vedolizumab 300 mgTotal
Female257
Male11617
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1: Vedolizumab 75 mgCohort 2: Vedolizumab 300 mgTotal
Hispanic or Latino022
Not Hispanic or Latino31821
Unknown or Not Reported011
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1: Vedolizumab 75 mgCohort 2: Vedolizumab 300 mgTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American011
White31922
More than one race000
Unknown or Not Reported011
Region of Enrollment
Region of Enrollment(Participants)Cohort 1: Vedolizumab 75 mgCohort 2: Vedolizumab 300 mgTotal
United States32124
Weight
Weight(kilogram (kg))Cohort 1: Vedolizumab 75 mgCohort 2: Vedolizumab 300 mgTotal
Mean92.93 ± 25.66289.96 ± 25.83690.33 ± 25.272
08

Study locations

5 sites
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 2215, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • OSU - James Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
  • Medical College of Wisconsin, Inc.
    Milwaukee, Wisconsin 53266, United States
09

References and documents

Publications

  • Chen YB, Shah NN, Renteria AS, Cutler C, Jansson J, Akbari M, Chen C, Quadri S, Parfionovas A, Devine SM. Vedolizumab for prevention of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood Adv. 2019 Dec 10;3(23):4136-4146. doi: 10.1182/bloodadvances.2019000893. PubMed 31821456 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Takeda makes patient-level, de-identified data sets and associated documents available after applicable marketing approvals and commercial availability have been received, an opportunity for the primary publication of the research has been allowed, and other criteria have been met as set forth in Takeda's Data Sharing Policy (see www.TakedaClinicalTrials.com/Approach for details). To obtain access, researchers must submit a legitimate academic research proposal for adjudication by an independent review panel, who will review the scientific merit of the research and the requestor's qualifications and conflict of interest that can result in potential bias. Once approved, qualified researchers who sign a data sharing agreement are provided access to these data in a secure research environment.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2016 to primary completion in Jul 2018, 24 months.

Results were first posted in Aug 2019, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2016
First posted
Apr 5, 2016
StartActual
Jun 15, 2016
Primary completionActual
Jul 10, 2018
CompletionActual
Jul 10, 2018
Results first posted
Aug 26, 2019
Last update
Aug 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02728895
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
Apr 5, 2016
Start date
Jun 15, 2016
Primary completion
Jul 10, 2018
Completion
Jul 10, 2018
Results posted
Aug 26, 2019
Last update
Aug 26, 2019

Study contacts

Medical Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vedolizumab

Start the discussion